Biological cost of fluoroquinolone resistance in Escherichia coli implicated in polyclonal infection

Pathologie Biologie

Volumn 55, Issue 6, 2007, Pages 288-291

  Bemer P ^a   Corvec, S ^a   Guitton, C ^b   Giraudeau, C ^a   Le Gargasson, G ^a   Espaze, E ^a   Drugeon, H ^a  

^a HÔTEL DIEU   (France)

^b Department of Intensive Care Unit ^*  (France)

Author keywords

Biological cost; E. coli; Polyclonal infection; Resistance to fluroquinolones

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; IMIPENEM; OFLOXACIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TICARCILLIN; QUINOLONE DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CASE REPORT; ESCHERICHIA COLI; GRAFT INFECTION; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MALE; PULSED FIELD GEL ELECTROPHORESIS; SEPTIC SHOCK; CHRONIC KIDNEY FAILURE; ENTEROBACTER INFECTION; FATALITY; MICROBIOLOGY; MIDDLE AGED; SURGICAL INFECTION;

DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI INFECTIONS; FATAL OUTCOME; FLUOROQUINOLONES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SURGICAL WOUND INFECTION;

EID: 34447528717     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2006.06.006     Document Type: Article

References (18)

1. Lindgren P.K., Karlsson A., and Hugues D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob. Agents Chemother. 47 (2003) 3222-3232
2. The application of pulse field gel electrophoresis to molecular epidemiology. In: Persing D.H., Smith T.F., Tenover F.C., and White T.J. (Eds). Diagnostic molecular microbiology: principles and applications (1993), American Society for Microbiology, Washington, DC 563-572
3. Tenover F.C., Arbeit R.D., Goering R.V., et al. Interpreting chromosomal DNA restriction patterns produced by pulse-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33 (1995) 2233-2239
4. Comité de l'antibiogramme de la Société française de microbiologie. Report of the Comité de l'Antibiogramme de la Société française de microbiologie. Technical recommendations for in vitro susceptibility (2005), Société française de microbiologie, Paris
5. Abbott K.C., Oliver J.D., Hypolite I., Lepler L.L., Kirk A.D., Ko C.W., et al. Hospitalizations for bacterial septicemia after renal transplantation in the United States. Am. J. Nephrol. 21 (2001) 120-127
6. Patel R. Infections in patients with kidney transplants. Infect. Dis. Clin. North Am. 15 (2001) 901-952
7. Oeschlaeger T.A., Ulrich D., and Joerg H. Virulence factors of uropathogens. Curr. Opin. Urol. 12 1 (2002) 33-38
8. In: Tintinalli J.E., Kelen G.D., and Stapczynski J.S. (Eds). Emergency medicine: a comprehensive study guide. 5th ed (2000), Univ. of North Carolina, McGraw Hill. Chapel Hill
9. LaRocco M.T., and Burgert S.J. Fungal infections in the transplant recipients and laboratory methods for diagnosis. Rev. Iberoam. Micol. 14 (1997) 143-146
10. Saenz Y., Zarazaga M., Brinas L., Ruiz-Larrea F., and Torres C. Mutations in gyrA and parC genes in nalidixic acid-resistant Escherichia coli strains from food products, humans and animals. J. Antimicrob. Chemother. 51 (2003) 1001-1005
11. Heisig P. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 40 (1996) 879-885
12. Hopkins K.L., Davies R.H., and Threlfal E.J.I. Mechanisms of quinolone resistance in Escherichia coli and Salmonella; Recent developments. Int. J. Antimicrob. Agents 25 (2005) 358-373
13. Vila J., Simon K., Ruiz J., Horcajada J.P., Velasco M., Barranco M., et al. Are quinolone-resistant uropathogenic Escherichia coli less virulent?. J. Infect. Dis. 186 (2002) 1039-1042
14. Bagel S., Hüllen V., Wiedemann B., and Heisig P. Impact of gyrA and parC mutations on quinolone resistance, doubling time, and supercoiling degree of Escherichia coli. Antimicrob. Agents Chemother. 43 (1999) 868-875
15. Lindgren P.K., Marcusson L.L., Sandvang D., Frimodt-Moller N., and Hugues D. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli umplicated in urinary tract infections. Antimicrob. Agents Chemother. 49 (2005) 2343-2351
16. Giraud E., Brisabois A., Martel J.L., and Chaslus-Dancla E. Comparative studies of mutations in animal isolates and experimental in vitro- and in vivo-selected mutants of Salmonella spp. suggest a counterselection of highly fluoroquinolone-resistant strains in the field. Antimicrob. Agents Chemother. 43 (1999) 2131-2137
17. Richard P., Delangle M.H., Merrien D., Barille S., Reynaud A., Minozzi C., et al. Fluoroquinolone use and fluoroquinolone resistance: is there an association?. Clin. Infect. Dis. 19 (1994) 54-59
18. Fendukly F., Karlsson I., Hanson H.S., Kronwall G., and Dornbusch K. Patterns of mutations in target genes in septicemia isolates of Escherichia coli and Klebsiella pneumoniae with resistance or reduced susceptibility to cirpofloxacin. APMIS 9 (2003) 857-866